Full text is available at the source.
Abstract
Oral semaglutide is associated with a signal for depression and suicidal ideation in individual patients.
- Large clinical trials have not shown increased psychiatric adverse events at the group level.
- Pharmacovigilance databases and case reports indicate a potential risk of neuropsychiatric issues.
- There is a suggestion of a dose-dependent onset for neuropsychiatric symptoms upon rechallenge.
- No previous reports have described this association specifically for the oral formulation.
Simplified